← Back to Clinical Trials
Recruiting NCT05942651

NCT05942651 Impulsivity With Borderline Personality Disorder/tMS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05942651
Status Recruiting
Phase
Sponsor Hôpital le Vinatier
Condition Borderline Personality Disorder
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-01-08
Primary Completion 2026-09-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 4 ms intervals.Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 100 ms intervals

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2024-01-08 with a primary completion date of 2026-09-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective, randomized, double-blind, parallel-group controlled trial. The aim of this research project is to compare the clinical benefits achieved in patients with Borderline Personality Disorder (BPD) following two types of intervention: ccPAS active or ccPAS sham.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of BPD (established by a psychiatrist and confirmed in a structured interview using the MINI) based on the Diagnostic and Statistical Manual of Mental Disorders (DSM V). Exclusion Criteria: * Contraindications to TMS/MRI (pacemakers or other devices likely to interfere with the magnetic field). * Pregnant or breast-feeding women. * Ongoing anxiolytic treatment (benzodiazepines), neuroleptic treatment or anticonvulsants acting on GABAergic transmission ; 24 hours prior to the protocol. * Diagnosis of other chronic psychiatric pathology including bipolar disorder type I or II and addictions (except tobacco). * Protective measure (curatorship or guardianship)

Contact & Investigator

Central Contact

POULET Emmanuel, PUPH

✉ emmanuel.poulet@chu-lyon.fr

📞 0437915565

Frequently Asked Questions

Who can join the NCT05942651 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Borderline Personality Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05942651 currently recruiting?

Yes, NCT05942651 is actively recruiting participants. Contact the research team at emmanuel.poulet@chu-lyon.fr for enrollment information.

Where is the NCT05942651 trial being conducted?

This trial is being conducted at Bron, France.

Who is sponsoring the NCT05942651 clinical trial?

NCT05942651 is sponsored by Hôpital le Vinatier. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology